Department of Neurosurgery, Beijing Boai Hospital, China Rehabilitation Research Center, and Capital Medical University School of Rehabilitation Medicine; Beijing, China.
Eur Rev Med Pharmacol Sci. 2019 Jan;23(1):271-276. doi: 10.26355/eurrev_201901_16773.
MicroRNAs (miRNAs) have been widely identified as potential biomarkers for predicting prognosis of glioma. The objective of the study was to examine the clinical role of plasma miR-124 expression in glioma.
MiR-124 expression in plasma samples from 64 cases glioma patients and 40 normal healthy controls was examined by quantitative reverse transcription PCR (qRT-PCR). The correlation of miR-124 expression with clinicopathological feathers or prognosis of glioma patients was assessed. Univariate and multivariate Cox analysis were used to analyze the risk factors of prognosis. The receiver operating characteristic (ROC) curve was established, and the area under the ROC curve (AUC) was calculated to evaluate the difference of miR-124 expression in glioma patients.
We showed that miR-124 expression was significantly downregulated in plasma samples of glioma patients compared with normal healthy controls (p<0.05). Plasma miR-124 expression significantly associated with Karnofsky Performance Status (KPS) score (p<0.05) and WHO grade (p<0.05) in glioma plasma. Patients with low miR-124 expression had worse disease free survival (DFS) and overall survival (OS) time than patients with high miR-124 expression. Univariate and multivariate analysis implied that low miR-124 expression was an independent maker of disease free survival (DFS) and overall survival (OS) in glioma.
Our findings implied that plasma miR-124 expression may serve as an independent predictor of poor prognosis.
microRNAs（miRNAs）已被广泛认为是预测胶质瘤预后的潜在生物标志物。本研究旨在研究血浆miR-124 表达在胶质瘤中的临床作用。
通过定量逆转录 PCR（qRT-PCR）检测 64 例胶质瘤患者和 40 例正常健康对照者血浆样本中的 miR-124 表达。评估 miR-124 表达与胶质瘤患者临床病理特征或预后的相关性。采用单因素和多因素 Cox 分析评估预后的危险因素。绘制受试者工作特征（ROC）曲线，计算 ROC 曲线下面积（AUC），评估 miR-124 在胶质瘤患者中的表达差异。
我们发现，与正常健康对照者相比，胶质瘤患者血浆样本中 miR-124 表达明显下调（p<0.05）。血浆 miR-124 表达与 Karnofsky 表现状态（KPS）评分（p<0.05）和胶质瘤 WHO 分级（p<0.05）显著相关。miR-124 低表达的患者无病生存（DFS）和总生存（OS）时间明显短于 miR-124 高表达的患者。单因素和多因素分析表明，miR-124 低表达是胶质瘤无病生存（DFS）和总生存（OS）的独立标志物。
我们的研究结果表明，血浆 miR-124 表达可能是预后不良的独立预测因子。
